Education
About Us
Working with TipRanks
Follow Us
Cibus, Inc. (CBUS)
:CBUS
CBUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.40 - $15.88
Previous CloseN/A
Volume64.89K
Average Volume (3M)144.59K
Market Cap
$97.14M
Enterprise ValueN/A
Total Cash (Recent Filing)$14.43M
Total Debt (Recent Filing)$36.29M
Price to Earnings (P/E)―
Beta2.64
Next Earnings
Aug 07, 2025EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding32,672,180
10 Day Avg. Volume152,724
30 Day Avg. Volume144,585
Financial Highlights & Ratios
PEG Ratio-4.11
Price to Book (P/B)570.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$22.00Price Target Upside680.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Cibus News
PremiumCompany Announcements
Cibus, Inc. Earnings Call: Achievements and Challenges
PremiumCompany Announcements
Cibus, Inc. Reports Q1 2025 Financial Results and Business Progress
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe recent endorsement by EU member states on the regulation of plants obtained by New Genomic Techniques could eventually translate into an expanded market opportunity for Cibus in Europe.
Regulatory ApprovalsCibus' disease resistance traits under development in Canola received an approval from the USDA's Animal and Plant Health Inspection Service, which determined that the gene-editing practices won't face higher regulatory scrutiny.
Revenue GrowthCibus' revenues increased by 135% year-over-year, mainly through collaboration agreements and sales related to developing a palm oil alternative.
Bears Say
Cash ReservesCibus has sufficient cash reserves to finance its capital requirements through late third quarter of the next year.
Financial PerformanceThe company produced a net loss of ~$47M, widening over 300% y/y, primarily due to a significant goodwill impairment charge.
Leadership ChangeCibus' CEO, Rory Riggs, will be stepping down from his leadership position, marking a significant leadership change.
Options Prices
Currently, No data available
---
Ownership Overview
27.57% Insiders
10.93% Mutual Funds
10.68% Other Institutional Investors
45.94% Public Companies and Individual Investors
CBUS FAQ
What was Cibus, Inc.’s price range in the past 12 months?
Cibus, Inc. lowest stock price was $1.40 and its highest was $15.88 in the past 12 months.
What is Cibus, Inc.’s market cap?
Cibus, Inc.’s market cap is $97.14M.
When is Cibus, Inc.’s upcoming earnings report date?
Cibus, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 76 days.
How were Cibus, Inc.’s earnings last quarter?
Cibus, Inc. released its earnings results on May 08, 2025. The company reported -$1.34 earnings per share for the quarter, missing the consensus estimate of -$0.583 by -$0.757.
Is Cibus, Inc. overvalued?
According to Wall Street analysts Cibus, Inc.’s price is currently Undervalued.
Does Cibus, Inc. pay dividends?
Cibus, Inc. does not currently pay dividends.
What is Cibus, Inc.’s EPS estimate?
Cibus, Inc.’s EPS estimate is -0.66.
How many shares outstanding does Cibus, Inc. have?
Cibus, Inc. has 32,672,180 shares outstanding.
What happened to Cibus, Inc.’s price movement after its last earnings report?
Cibus, Inc. reported an EPS of -$1.34 in its last earnings report, missing expectations of -$0.583. Following the earnings report the stock price went down -8.936%.
Which hedge fund is a major shareholder of Cibus, Inc.?
Currently, no hedge funds are holding shares in CBUS
Cibus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (680.14% Upside)
$22.00 (680.14% Upside)
Blogger Sentiment
Bullish
CBUS Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $24.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.92%
12-Months-Change
Fundamentals
Return on Equity
-157.73%
Trailing 12-Months
Asset Growth
-37.14%
Trailing 12-Months
Company Description
Cibus, Inc.
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
CBUS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in regulatory milestones and commercial strategy validation, particularly in gene editing and sustainable ingredients. However, financial results showed increased net loss and SG&A expenses, raising concerns about cash burn and profitability.Read More>CBUS Stock 12 Month Forecast
Average Price Target
$22.00
▲( 680.14% Upside)
Technical Analysis
Avalo Therapeutics
―
Inozyme Pharma
―
Kronos Bio
―
Gain Therapeutics
―
Metagenomi, Inc.
―